1
|
Liu C, Lei S, Cai T, Cheng Y, Bai J, Fu W, Huang M. Inducible nitric oxide synthase activity mediates TNF-α-induced endothelial cell dysfunction. Am J Physiol Cell Physiol 2023; 325:C780-C795. [PMID: 37575057 DOI: 10.1152/ajpcell.00153.2023] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Revised: 08/03/2023] [Accepted: 08/03/2023] [Indexed: 08/15/2023]
Abstract
Inducible nitric oxide synthase (iNOS) and vascular endothelial dysfunction have been implicated in the development and progression of atherosclerosis. This study aimed to elucidate the role of iNOS in vascular endothelial dysfunction. Ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry combined with multivariate data analysis was used to characterize the metabolic changes in human umbilical vein endothelial cells (HUVECs) in response to different treatment conditions. In addition, molecular biology techniques were employed to explain the molecular mechanisms underlying the role of iNOS in vascular endothelial dysfunction. Tumor necrosis factor-α (TNF-α) enhances the expression of iNOS, TXNIP, and the level of reactive oxygen species (ROS) facilitates the entry of nuclear factor-κB (NF-κB) into the nucleus and promotes injury in HUVECs. iNOS deficiency reversed the TNF-α-mediated pathological changes in HUVECs. Moreover, TNF-α increased the expression of tumor necrosis factor receptor-2 (TNFR-2) and the levels of p-IκBα and IL-6 proteins and CD31, ICAM-1, and VCAM-1 protein expression, which was significantly reduced in HUVECs with iNOS deficiency. In addition, treating HUVECs in the absence or presence of TNF-α or iNOS, respectively, enabled the identification of putative endogenous biomarkers associated with endothelial dysfunction. These biomarkers were involved in critical metabolic pathways, including glycosylphosphatidylinositol-anchor biosynthesis, amino acid metabolism, sphingolipid metabolism, and fatty acid metabolism. iNOS deficiency during vascular endothelial dysfunction may affect the expression of TNFR-2, vascular adhesion factors, and the level of ROS via cellular metabolic changes, thereby attenuating vascular endothelial dysfunction.NEW & NOTEWORTHY Inducible nitric oxide synthase (iNOS) deficiency during vascular endothelial dysfunction may affect the expression of tumor necrosis factor receptor-2 and vascular adhesion factors via cellular metabolic changes, thereby attenuating vascular endothelial dysfunction.
Collapse
Affiliation(s)
- Chen Liu
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Sujuan Lei
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Tianying Cai
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Yonglang Cheng
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Junjie Bai
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Wenguang Fu
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
- Academician (Expert) Workstation of Sichuan Province, Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| | - Meizhou Huang
- Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
- Academician (Expert) Workstation of Sichuan Province, Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China
| |
Collapse
|
2
|
Okoro EU. TNFα-Induced LDL Cholesterol Accumulation Involve Elevated LDLR Cell Surface Levels and SR-B1 Downregulation in Human Arterial Endothelial Cells. Int J Mol Sci 2021; 22:ijms22126236. [PMID: 34207810 PMCID: PMC8227244 DOI: 10.3390/ijms22126236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/06/2021] [Accepted: 06/07/2021] [Indexed: 12/18/2022] Open
Abstract
Excess lipid droplets are frequently observed in arterial endothelial cells at sites of advanced atherosclerotic plaques. Here, the role of tumor necrosis factor alpha (TNFα) in modulating the low-density lipoprotein (LDL) content in confluent primary human aortic endothelial cells (pHAECs) was investigated. TNFα promoted an up to 2 folds increase in cellular cholesterol, which was resistant to ACAT inhibition. The cholesterol increase was associated with increased 125I-LDL surface binding. Using the non-hydrolysable label, Dil, TNFα could induce a massive increase in Dil-LDL by over 200 folds. The elevated intracellular Dil-LDL was blocked with excess unlabeled LDL and PCSK9, but not oxidized LDL (oxLDL), or apolipoprotein (apoE) depletion. Moreover, the TNFα-induced increase of LDL-derived lipids was elevated through lysosome inhibition. Using specific LDLR antibody, the Dil-LDL accumulation was reduced by over 99%. The effects of TNFα included an LDLR cell surface increase of 138%, and very large increases in ICAM-1 total and surface proteins, respectively. In contrast, that of scavenger receptor B1 (SR-B1) was reduced. Additionally, LDLR antibody bound rapidly in TNFα-treated cells by about 30 folds, inducing a migrating shift in the LDLR protein. The effect of TNFα on Dil-LDL accumulation was inhibited by the antioxidant tetramethythiourea (TMTU) dose-dependently, but not by inhibitors against NF-κB, stress kinases, ASK1, JNK, p38, or apoptosis caspases. Grown on Transwell inserts, TNFα did not enhance apical to basolateral LDL cholesterol or Dil release. It is concluded that TNFα promotes LDLR functions through combined increase at the cell surface and SR-B1 downregulation.
Collapse
Affiliation(s)
- Emmanuel Ugochukwu Okoro
- Department of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, TN 37208, USA
| |
Collapse
|
3
|
|
4
|
Nicolaou A, Zhao Z, Northoff BH, Sass K, Herbst A, Kohlmaier A, Chalaris A, Wolfrum C, Weber C, Steffens S, Rose-John S, Teupser D, Holdt LM. Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice. Arterioscler Thromb Vasc Biol 2016; 37:247-257. [PMID: 28062509 DOI: 10.1161/atvbaha.116.308682] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Accepted: 11/28/2016] [Indexed: 12/31/2022]
Abstract
OBJECTIVE ADAM17 (a disintegrin and metalloproteinase 17) is a sheddase releasing different types of membrane-bound proteins, including adhesion molecules, cytokines, and their receptors as well as inflammatory mediators. Because these substrates modulate important mechanisms of atherosclerosis, we hypothesized that ADAM17 might be involved in the pathogenesis of this frequent disease. APPROACH AND RESULTS Because Adam17-knockout mice are not viable, we studied the effect of Adam17 deficiency on atherosclerosis in Adam17 hypomorphic mice (Adam17ex/ex), which have low residual Adam17 expression. To induce atherosclerosis, mice were crossed onto the low-density lipoprotein receptor (Ldlr)-deficient background. We found that Adam17ex/ex.Ldlr-/- mice developed ≈1.5-fold larger atherosclerotic lesions, which contained more macrophages and vascular smooth muscle cells than wild-type littermate controls (Adam17wt/wt.Ldlr-/-). Reduced Adam17-mediated shedding led to significantly increased protein levels of membrane-resident TNFα (tumor necrosis factor) and TNFR2 (tumor necrosis factor receptor 2), resulting in a constitutive activation of TNFR2 signaling. At the same time, Adam17 deficiency promoted proatherosclerotic cellular functions, such as increased proliferation and reduced apoptosis in cultured macrophages and vascular smooth muscle cells and increased adhesion of macrophages to vascular endothelial cells. Because siRNA (small interfering RNA)-mediated knockdown of Tnfr2 rescued from aberrant proliferation and from misregulation of apoptosis in Adam17-depleted cells, our data indicate that TNFR2 is an important effector of ADAM17 in our mouse model. CONCLUSIONS Our results provide evidence for an atheroprotective role of ADAM17, which might be mediated by cleaving membrane-bound TNFα and TNFR2, thereby preventing overactivation of endogenous TNFR2 signaling in cells of the vasculature.
Collapse
Affiliation(s)
- Alexandros Nicolaou
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Zhen Zhao
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Bernd H Northoff
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Kristina Sass
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Andreas Herbst
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Alexander Kohlmaier
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Athena Chalaris
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Christian Wolfrum
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Christian Weber
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Sabine Steffens
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Stefan Rose-John
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Daniel Teupser
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.)
| | - Lesca M Holdt
- From the Institute of Laboratory Medicine (A.N., B.H.N., K.S., A.H., A.K., D.T., L.M.H.) and Institute for Cardiovascular Prevention (Z.Z., C.Weber, S.S.), Ludwig-Maximilians-University Munich, Germany; Institute of Biochemistry, Christian Albrechts University, Kiel, Germany (A.C., S.R.-J.); Institute of Food, Nutrition and Health, ETH Zurich, Schwerzenbach, Switzerland (C.Wolfrum); and German Centre for Cardiovascular Research, partner site Munich Heart Alliance, Germany (C. Weber, S.S.).
| |
Collapse
|
5
|
Zhong QQ, Wang X, Li YF, Peng LJ, Jiang ZS. Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis. Exp Biol Med (Maywood) 2016; 242:250-257. [PMID: 27698252 DOI: 10.1177/1535370216672747] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Secretory leukocyte protease inhibitor (SLPI), a serine protease inhibitor, which was most commonly examined in mucosal fluids such as saliva, is a versatile molecule and plays non-redundant roles. In addition to its anti-protease activity, SLPI has been shown to express anti-bacterial, anti-viral, anti-fungal, and anti-inflammatory properties as well as participating in innate and adaptive immune responses, most of which has been well documented. Recently, it is reported that SLPI is expressed in adipocytes and adipose tissue where it could play an important feedback role in the resolution of inflammation. Furthermore, circulating SLPI has been shown to correlate with progressive metabolic dysfunction. Moreover, adenoviral gene delivery of elafin and SLPI attenuates nuclear factor-κB-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. This review contributes to unraveling the protective role of SLPI in obesity-related atherosclerosis development, and the potential role in preventing arterial plaque rupture.
Collapse
Affiliation(s)
- Qiao-Qing Zhong
- 1 Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China.,2 Post-doctoral Mobile Stations for Basic Medicine, Institute of Cardiovascular Disease and Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang 421001, China.,3 Department of Cardiology, First People's Hospital of Chenzhou, University of South China, Chenzhou 423000, China
| | - Xiang Wang
- 3 Department of Cardiology, First People's Hospital of Chenzhou, University of South China, Chenzhou 423000, China
| | - Yun-Feng Li
- 3 Department of Cardiology, First People's Hospital of Chenzhou, University of South China, Chenzhou 423000, China
| | - Li-Jun Peng
- 2 Post-doctoral Mobile Stations for Basic Medicine, Institute of Cardiovascular Disease and Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang 421001, China.,4 Department of Science and Teaching, Children's Hospital of Hunan Province, Changsha 410007, China
| | - Zhi-Sheng Jiang
- 2 Post-doctoral Mobile Stations for Basic Medicine, Institute of Cardiovascular Disease and Key Lab for Arteriosclerology of Hunan Province, University of South China, Hengyang 421001, China
| |
Collapse
|
6
|
Zhai K, Tang Y, Zhang Y, Li F, Wang Y, Cao Z, Yu J, Kou J, Yu B. NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium. Thromb Haemost 2015; 114:173-85. [PMID: 25881103 DOI: 10.1160/th14-10-0880] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Accepted: 02/19/2015] [Indexed: 01/29/2023]
Abstract
Non-muscle myosin heavy chain IIA (NMMHC IIA) has been shown to be involved in thrombus formation and inflammatory microparticle release in endothelial cells. However, the role of NMMHC IIA in regulating the expression of tissue factor (TF) and deep venous thrombosis remains to be elucidated. In the present study, endothelial cells were stimulated with tumour necrosis factor-α (TNF-α) to induce TF expression. Pretreatment with the NMMHC II inhibitor blebbistatin suppressed the mRNA and protein expressions as well as the procoagulant activity of TF in a dose-dependent manner. Blebbistatin enhanced Akt and GSK3β phosphorylation and inhibited NF-κB p65 nuclear translocation and IκBα degradation. These observations were similar to the effect of CHIR99021, a GSK3β inhibitor. TF downregulation by blebbistatin was antagonised by the PI3K inhibitor, wortmannin. Furthermore, siRNA knockdown of NMMHC IIA, but not IIB or IIC, inhibited TF expression, activated Akt/GSK3β and suppressed NF-κB signalling pathways, whereas the overexpression of NMMHC IIA increased TF expression. The binding of NMMHC IIA and TNF receptor 2 mediated signal internalisation in TNF-α-stimulated endothelial cells. Importantly, blebbistatin decreased endothelium NMMHC IIA and TF expression, deactivated GSK3β by inducing its phosphorylation, suppressed p65 nuclear translocation, and inhibited thrombus formation in a mouse deep venous thrombosis model.Our findings provide solid evidence that inhibition of NMMHC II, most likely NMMHC IIA, impedes TF expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium both in vitro and in vivo. NMMHC IIA might be a potential novel target for the treatment of thrombotic disorders.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jun Yu
- Dr. Jun Yu, Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT 06519, USA, Tel.: +1 203 7372869, Fax: +1 203 7372290, E-mail:
| | - Junping Kou
- Dr. Junping Kou, State Key Laboratory of Natural Products, Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Complex Prescription of TCM, China Pharmaceutical University, 639 Longmian Road, Nanjing, 211198, P. R. China, Tel./Fax: +86 25 86185158, E-mail:
| | | |
Collapse
|
7
|
Differential inflammasome activation by Porphyromonas gingivalis and cholesterol crystals in human macrophages and coronary artery endothelial cells. Atherosclerosis 2014; 235:38-44. [DOI: 10.1016/j.atherosclerosis.2014.04.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Revised: 02/19/2014] [Accepted: 04/07/2014] [Indexed: 11/23/2022]
|
8
|
Teng B, Smith JD, Rosenfeld ME, Robinet P, Davis ME, Morrison RR, Mustafa SJ. A₁ adenosine receptor deficiency or inhibition reduces atherosclerotic lesions in apolipoprotein E deficient mice. Cardiovasc Res 2014; 102:157-65. [PMID: 24525840 DOI: 10.1093/cvr/cvu033] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
AIMS The goal of this study was to determine whether the A1 adenosine receptor (AR) plays a role in atherosclerosis development and to explore its potential mechanisms. METHODS AND RESULTS Double knockout (DKO) mice, deficient in the genes encoding A1 AR and apolipoprotein E (apoE), demonstrated reduced atherosclerotic lesions in aortic arch (en face), aortic root, and innominate arteries when compared with apoE-deficient mice (APOE-KO) of the same age. Treating APOE-KO with an A1 AR antagonist (DPCPX) also led to a concentration-dependent reduction in lesions. The total plasma cholesterol and triglyceride levels were not different between DKO and APOE-KO; however, higher triglyceride was observed in DKO fed a high-fat diet. DKO also had higher body weights than APOE-KO. Plasma cytokine concentrations (IL-5, IL-6, and IL-13) were significantly lower in DKO. Proliferating cell nuclear antigen expression was also significantly reduced in the aorta from DKO. Despite smaller lesions in DKO, the composition of the innominate artery lesion and cholesterol loading and efflux from bone marrow-derived macrophages of DKO were not different from APOE-KO. CONCLUSION The A1 AR may play a role in the development of atherosclerosis, possibly due to its pro-inflammatory and mitogenic properties.
Collapse
Affiliation(s)
- Bunyen Teng
- Department of Physiology and Pharmacology, Center for Cardiovascular and Respiratory Sciences, West Virginia University, 1 Medical Center Drive, Morgantown, WV, USA
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
At least 468 individual genes have been manipulated by molecular methods to study their effects on the initiation, promotion, and progression of atherosclerosis. Most clinicians and many investigators, even in related disciplines, find many of these genes and the related pathways entirely foreign. Medical schools generally do not attempt to incorporate the relevant molecular biology into their curriculum. A number of key signaling pathways are highly relevant to atherogenesis and are presented to provide a context for the gene manipulations summarized herein. The pathways include the following: the insulin receptor (and other receptor tyrosine kinases); Ras and MAPK activation; TNF-α and related family members leading to activation of NF-κB; effects of reactive oxygen species (ROS) on signaling; endothelial adaptations to flow including G protein-coupled receptor (GPCR) and integrin-related signaling; activation of endothelial and other cells by modified lipoproteins; purinergic signaling; control of leukocyte adhesion to endothelium, migration, and further activation; foam cell formation; and macrophage and vascular smooth muscle cell signaling related to proliferation, efferocytosis, and apoptosis. This review is intended primarily as an introduction to these key signaling pathways. They have become the focus of modern atherosclerosis research and will undoubtedly provide a rich resource for future innovation toward intervention and prevention of the number one cause of death in the modern world.
Collapse
Affiliation(s)
- Paul N Hopkins
- Cardiovascular Genetics, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
| |
Collapse
|
10
|
Chandrasekharan UM, Dechert L, Davidson UI, Waitkus M, Mavrakis L, Lyons K, Beach JR, Li X, Egelhoff TT, Fox PL, DiCorleto PE. Release of nonmuscle myosin II from the cytosolic domain of tumor necrosis factor receptor 2 is required for target gene expression. Sci Signal 2013; 6:ra60. [PMID: 23861542 DOI: 10.1126/scisignal.2003743] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Tumor necrosis factor-α (TNF-α) elicits its biological activities through activation of TNF receptor 1 (TNFR1, also known as p55) and TNFR2 (also known as p75). The activities of both receptors are required for the TNF-α-induced proinflammatory response. The adaptor protein TNFR-associated factor 2 (TRAF2) is critical for either p55- or p75-mediated activation of nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling, as well as for target gene expression. We identified nonmuscle myosin II (myosin) as a binding partner of p75. TNF-α-dependent signaling by p75 and induction of target gene expression persisted substantially longer in cells deficient in myosin regulatory light chain (MRLC; a component of myosin) than in cells replete in myosin. In resting endothelial cells, myosin was bound constitutively to the intracellular region of p75, a region that overlaps with the TRAF2-binding domain, and TNF-α caused the rapid dissociation of myosin from p75. At early time points after exposure to TNF-α, p75 activated Rho-associated kinase 1 (ROCK1). Inhibition of ROCK1 activity blocked TNF-α-dependent phosphorylation of MRLC and the dissociation of myosin from p75. ROCK1-dependent release of myosin was necessary for the TNF-α-dependent recruitment of TRAF2 to p75 and for p75-specific activation of NF-κB and MAPK signaling. Thus, our findings have revealed a previously uncharacterized, noncanonical regulatory function of myosin in cytokine signaling.
Collapse
Affiliation(s)
- Unni M Chandrasekharan
- Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Pircher J, Merkle M, Wörnle M, Ribeiro A, Czermak T, Stampnik Y, Mannell H, Niemeyer M, Vielhauer V, Krötz F. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther 2012; 14:R225. [PMID: 23079185 PMCID: PMC3580536 DOI: 10.1186/ar4064] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2012] [Accepted: 10/05/2012] [Indexed: 01/20/2023] Open
Abstract
Introduction Elevated serum levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFα) correlate with an increased risk for atherothrombotic events and TNFα is known to induce prothrombotic molecules in endothelial cells. Based on the preexisting evidence for the impact of TNFα in the pathogenesis of autoimmune disorders and their known association with an acquired hypercoagulability, we investigated the effects of TNFα and the role of the TNF receptor subtypes TNFR1 and TNFR2 for arteriolar thrombosis in vivo. Methods Arteriolar thrombosis and platelet-rolling in vivo were investigated in wildtype, TNFR1-/-, TNFR2-/- and TNFR1-/R2-/- C57BL/6 mice using intravital microscopy in the dorsal skinfold chamber microcirculation model. In vitro, expression of prothrombotic molecules was assessed in human endothelial cells by real-time PCR and flow cytometry. Results In wildtype mice, stimulation with TNFα significantly accelerated thrombotic vessel occlusion in vivo upon ferric chloride injury. Arteriolar thrombosis was much more pronounced in TNFR1-/- animals, where TNFα additionally led to increased platelet-endothelium-interaction. TNFα dependent prothrombotic effects were not observed in TNFR2-/- and TNFR1-/R2- mice. In vitro, stimulation of human platelet rich plasma with TNFα did not influence aggregation properties. In human endothelial cells, TNFα induced superoxide production, p-selectin, tissue factor and PAI-1, and suppressed thrombomodulin, resulting in an accelerated endothelial dependent blood clotting in vitro. Additionally, TNFα caused the release of soluble mediators by endothelial cells which induced prothrombotic and suppressed anticoagulant genes comparable to direct TNFα effects. Conclusions TNFα accelerates thrombus formation in an in vivo model of arteriolar thrombosis. Its prothrombotic effects in vivo require TNFR2 and are partly compensated by TNFR1. In vitro studies indicate endothelial mechanisms to be responsible for prothrombotic TNFα effects. Our results support a more selective therapeutic approach in anticytokine therapy favouring TNFR2 specific antagonists.
Collapse
|
12
|
Ji W, Li Y, Wan T, Wang J, Zhang H, Chen H, Min W. Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling. Arterioscler Thromb Vasc Biol 2012; 32:2271-9. [PMID: 22743059 DOI: 10.1161/atvbaha.112.253666] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE The proinflammtory cytokine tumor necrosis factor (TNF), primarily via TNF receptor 1 (TNFR1), induces nuclear factor-κB (NF-κB)-dependent cell survival, and c-Jun N-terminal kinase (JNK) and caspase-dependent cell death, regulating vascular endothelial cell (EC) activation and apoptosis. However, signaling by the second receptor, TNFR2, is poorly understood. The goal of this study was to dissect how TNFR2 mediates NF-κB and JNK signaling in vascular EC, and its relevance to in vivo EC function. METHODS AND RESULTS We show that TNFR2 contributes to TNF-induced NF-κB and JNK signaling in EC as TNFR2 deletion or knockdown reduces the TNF responses. To dissect the critical domains of TNFR2 that mediate the TNF responses, we examine the activity of TNFR2 mutant with a specific deletion of the TNFR2 intracellular region, which contains conserved domain I, domain II, domain III, and 2 TNFR-associated factor-2-binding sites. Deletion analyses indicate that different sequences on TNFR2 have distinct roles in NF-κB and JNK activation. Specifically, deletion of the TNFR-associated factor-2-binding sites (TNFR2-59) diminishes the TNFR2-mediated NF-κB, but not JNK activation; whereas, deletion of domain II or domain III blunts TNFR2-mediated JNK but not NF-κB activation. Interestingly, we find that the TNFR-associated factor-2-binding sites ensure TNFR2 on the plasma membrane, but the di-leucine LL motif within the domain II and aa338-355 within the domain III are required for TNFR2 internalization as well as TNFR2-dependent JNK signaling. Moreover, domain III of TNFR2 is responsible for association with ASK1-interacting protein-1, a signaling adaptor critical for TNF-induced JNK signaling. While TNFR2 containing the TNFR-associated factor-2-binding sites prevents EC cell death, a specific activation of JNK without NF-κB activation by TNFR2-59 strongly induces caspase activation and EC apoptosis. CONCLUSIONS Our data reveal that both internalization and ASK1-interacting protein-1 association are required for TNFR2-dependent JNK and apoptotic signaling. Controlling TNFR2-mediated JNK and apoptotic signaling in EC may provide a novel strategy for the treatment of vascular diseases.
Collapse
Affiliation(s)
- Weidong Ji
- Interdepartmental Program in Vascular Biology and Therapeutics, Yale University School of Medicine, 10 Amistad St., 401B, New Haven, CT 06520, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med 2011; 43:90-103. [PMID: 21039303 DOI: 10.3109/07853890.2010.523711] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Accumulating evidence suggests that inflammatory pathways play an essential role in all stages of atherogenesis. Inflammatory processes are not only involved in plaque progression, but seem also to play a critical role in plaque rupture. Members of the tumor necrosis factor (TNF) superfamiliy are potent regulators of inflammation and cell survival and consist of 20 ligands that signal through 29 different receptors. Several lines of evidence suggest that TNF-related molecules are involved in the development of acute coronary syndromes (ACS). Most, convincing evidence exists for CD40 ligand-CD40 interaction, but several other members of the TNF superfamily seem also to be involved in this immune-mediated promotion of plaque instability, including LIGHT, receptor activator of nuclear factor κB ligand, and TNF-α. These plaque destabilization pathways involve the bidirectional interaction between platelets and endothelial cells/monocytes, activation of vascular smooth muscle cells, and co-stimulatory effects on T cells, promoting inflammation, thrombus formation, matrix degradation, and apoptosis. TNF-related pathways could contribute to the non-resolving inflammation that characterizes atherosclerosis, representing pathogenic loops that are operating during plaque rupture and the development of ACS. These TNF-related molecules could also represent attractive new targets for therapy in this disorder.
Collapse
Affiliation(s)
- Pål Aukrust
- Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Loppnow H, Buerke M, Werdan K, Rose-John S. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med 2011; 15:484-500. [PMID: 21199323 PMCID: PMC3922371 DOI: 10.1111/j.1582-4934.2010.01245.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2010] [Accepted: 12/21/2010] [Indexed: 01/22/2023] Open
Abstract
Inflammation is a central element of atherogenesis. Innate pathways contribute to vascular inflammation. However, the initial molecular process(es) starting atherogenesis remain elusive. The various risk factors, represented by particular compounds (activators), may cause altered cellular functions in the endothelium (e.g. vascular endothelial cell activation or -dysfunction), in invading cells (e.g. inflammatory mediator production) or in local vessel wall cells (e.g. inflammatory mediators, migration), thereby triggering the innate inflammatory process. The cellular components of innate immunology include granulocytes, natural killer cells and monocytes. Among the molecular innate constituents are innate molecules, such as the toll-like receptors or innate cytokines. Interleukin-1 (IL-1) and IL-6 are among the innate cytokines. Cytokines are potent activators of a great number of cellular functions relevant to maintain or commove homeostasis of the vessel wall. Within the vessel wall, vascular smooth muscle cells (SMCs) can significantly contribute to the cytokine-dependent inflammatory network by: (i) production of cytokines, (ii) response to cytokines and (iii) cytokine-mediated interaction with invading leucocytes. The cytokines IL-1 and IL-6 are involved in SMC-leucocyte interaction. The IL-6 effects are proposed to be mediated by trans-signalling. Dysregulated cellular functions resulting from dysregulated cytokine production may be the cause of cell accumulation, subsequent low-density lipoprotein accumulation and deposition of extracellular matrix (ECM). The deposition of ECM, increased accumulation of leucocytes and altered levels of inflammatory mediators may constitute an 'innate-immunovascular-memory' resulting in an ever-growing response to anew invasion. Thus, SMC-fostered inflammation, promoted by invading innate cells, may be a potent component for development and acceleration of atherosclerosis.
Collapse
Affiliation(s)
- Harald Loppnow
- Department of Internal Medicine III, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
| | | | | | | |
Collapse
|
15
|
Shen J, Chandrasekharan UM, Ashraf MZ, Long E, Morton RE, Liu Y, Smith JD, DiCorleto PE. Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ Res 2010; 106:902-10. [PMID: 20093631 DOI: 10.1161/circresaha.109.198069] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
RATIONALE Multiple protein kinases have been implicated in cardiovascular disease; however, little is known about the role of their counterparts: the protein phosphatases. OBJECTIVE To test the hypothesis that mitogen-activated protein kinase phosphatase (MKP)-1 is actively involved in atherogenesis. METHODS AND RESULTS Mice with homozygous deficiency in MKP-1 (MKP-1(-/-)) were bred with apolipoprotein (Apo)E-deficient mice (ApoE(-/-)) and the 3 MKP-1 genotypes (MKP-1(+/+)/ApoE(-/-) ; MKP-1(+/-)/ApoE(-/-) and MKP-1(-/-)/ApoE(-/-)) were maintained on a normal chow diet for 16 weeks. The 3 groups of mice exhibited similar body weight and serum lipid profiles; however, both MKP-1(+/-) and MKP-1(-/-) mice had significantly less aortic root atherosclerotic lesion formation than MKP-1(+/+) mice. Less en face lesion was observed in 8-month-old MKP-1(-/-) mice. The reduction in atherosclerosis was accompanied by decreased plasma levels of interleukin-1alpha and tumor necrosis factor alpha, and preceded by increased antiinflammatory cytokine interleukin-10. In addition, MKP-1-null mice had higher levels of plasma stromal cell-derived factor-1a, which negatively correlated with atherosclerotic lesion size. Immunohistochemical analysis revealed that MKP-1 expression was enriched in macrophage-rich areas versus smooth muscle cell regions of the atheroma. Furthermore, macrophages isolated from MKP-1-null mice showed dramatic defects in their spreading/migration and impairment in extracellular signal-regulated kinase, but not c-Jun N-terminal kinase and p38, pathway activation. In line with this, MKP-1-null atheroma exhibited less macrophage content. Finally, transplantation of MKP-1-intact bone marrow into MKP-1-null mice fully rescued the wild-type atherosclerotic phenotype. CONCLUSION These findings demonstrate that chronic deficiency of MKP-1 leads to decreased atherosclerosis via mechanisms involving impaired macrophage migration and defective extracellular signal-regulated kinase signaling.
Collapse
Affiliation(s)
- Jianzhong Shen
- Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Ohio 44195, USA.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Rauert H, Wicovsky A, Müller N, Siegmund D, Spindler V, Waschke J, Kneitz C, Wajant H. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 2009; 285:7394-404. [PMID: 20038584 DOI: 10.1074/jbc.m109.037341] [Citation(s) in RCA: 135] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Tumor necrosis factor (TNF) elicits its biological activities by stimulation of two receptors, TNFR1 and TNFR2, both belonging to the TNF receptor superfamily. Whereas TNFR1-mediated signal transduction has been intensively studied and is understood in detail, especially with respect to activation of the classical NFkappaB pathway, cell death induction, and MAP kinase signaling, TNFR2-associated signal transduction is poorly defined. Here, we demonstrate in various tumor cell lines and primary T-cells that TNFR2, but not TNFR1, induces activation of the alternative NFkappaB pathway. In accord with earlier findings demonstrating that only membrane TNF, but not soluble TNF, properly activates TNFR2, we further show by use of TNFR1- and TNFR2-specific mutants of soluble TNF and membrane TNF that soluble ligand trimers fail to activate the alternative NFkappaB pathway. In accord with the known inhibitory role of TRAF2 in the alternative NFkappaB pathway, TNFR2-, but not TNFR1-specific TNF induced depletion of cytosolic TRAF2. Thus, we identified activation of the alternative NFkappaB pathway as a TNF signaling effect that can be specifically assigned to TNFR2 and membrane TNF.
Collapse
Affiliation(s)
- Hilka Rauert
- Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Röntgenring 11, 97070 Würzburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, Kockx MM, Daemen MJ, Heeneman S. Fn14-Fc Fusion Protein Regulates Atherosclerosis in ApoE
−/−
Mice and Inhibits Macrophage Lipid Uptake In Vitro. Arterioscler Thromb Vasc Biol 2009; 29:2021-7. [DOI: 10.1161/atvbaha.109.195040] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
TWEAK is a multifunctional cytokine belonging to the tumor necrosis factor superfamily and binds to the receptor Fn14. TWEAK and Fn14 are expressed in atherosclerotic plaques in areas rich in macrophages and foam cells. We investigated the role of TWEAK/Fn14 interactions in ApoE
−/−
mice and bone marrow–derived macrophages in vitro.
Methods and Results—
ApoE
−/−
mice were treated with TWEAK-inhibiting fusion protein, Fn14-Fc, in an early (5 to 17 weeks of age) or delayed (17 to 29 weeks of age) setting. In the aortic arch, Fn14-Fc as compared to control treatment resulted in advanced plaques which were smaller (early treatment), fewer (delayed treatment), lower in fibrotic content (early and delayed treatment), and exhibited an increased macrophage content and smaller macrophage size (delayed treatment). There were no differences in apoptosis in atherosclerotic plaques after Fn14-Fc versus control Ab treatment. However, blocking TWEAK resulted in less macrophage uptake of modified lipids in vitro.
Conclusions—
Fn14-Fc fusion protein treatment did not prevent lesion initiation but inhibited some features of plaque progression and induced a unique advanced plaque phenotype with increased macrophage content and smaller macrophage size, which may be attributable to reduced lipid uptake. These findings indicate that TWEAK/Fn14 interactions regulate atherosclerosis and mediate lipid uptake in macrophages.
Collapse
Affiliation(s)
- Kitty Schapira
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Linda C. Burkly
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Timothy S. Zheng
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Ping Wu
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Mathijs Groeneweg
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Mat Rousch
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Mark M. Kockx
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Mat J.A.P. Daemen
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| | - Sylvia Heeneman
- From the Department of Pathology (K.S., M.G., M.R., M.J.A.P.D., S.H.), Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands; the Department of Immunobiology (L.C.B., T.S.Z., P.W.), Biogen Idec, Cambridge, Mass; and the Department of Pathology (M.M.K.), Middelheim Hospital, Antwerp, Belgium
| |
Collapse
|
18
|
Loppnow H, Werdan K, Buerke M. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun 2008; 14:63-87. [PMID: 18713724 DOI: 10.1177/1753425908091246] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Cardiovascular diseases are the human diseases with the highest death rate and atherosclerosis is one of the major underlying causes of cardiovascular diseases. Inflammatory and innate immune mechanisms, employing monocytes, innate receptors, innate cytokines, or chemokines are suggested to be involved in atherogenesis. Among the inflammatory pathways the cytokines are central players. Plasma levels of cytokines and related proteins, such as CRP, have been investigated in cardiovascular patients, tissue mRNA expression was analyzed and correlations to vascular diseases established. Consistent with these findings the generation of cytokine-deficient animals has provided direct evidence for a role of cytokines in atherosclerosis. In vitro cell culture experiments further support the suggestion that cytokines and other innate mechanisms contribute to atherogenesis. Among the initiation pathways of atherogenesis are innate mechanisms, such as toll-like-receptors (TLRs), including the endotoxin receptor TLR4. On the other hand, innate cytokines, such as IL-1 or TNF, or even autoimmune triggers may activate the cells. Cytokines potently activate multiple functions relevant to maintain or spoil homeostasis within the vessel wall. Vascular cells, not least smooth muscle cells, can actively contribute to the inflammatory cytokine-dependent network in the blood vessel wall by: (i) production of cytokines; (ii) response to these potent cell activators; and (iii) cytokine-mediated interaction with invading cells, such as monocytes, T-cells, or mast cells. Activation of these pathways results in accumulation of cells and increased LDL- and ECM-deposition which may serve as an 'immunovascular memory' resulting in an ever-growing response to subsequent invasions. Thus, vascular cells may potently contribute to the inflammatory pathways involved in development and acceleration of atherosclerosis.
Collapse
Affiliation(s)
- Harald Loppnow
- Martin-Luther-Universität Halle-Wittenberg, Universitätsklinik und Poliklinik für Innere Medizin , Halle (Saale), Germany.
| | | | | |
Collapse
|
19
|
Xanthoulea S, Gijbels MJJ, van der Made I, Mujcic H, Thelen M, Vergouwe MN, Ambagts MHC, Hofker MH, de Winther MPJ. P55 tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice. Cardiovasc Res 2008; 80:309-18. [PMID: 18628255 DOI: 10.1093/cvr/cvn193] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS Tumour necrosis factor (TNF) is a pivotal pro-inflammatory cytokine with a clear pathogenic role in many chronic inflammatory diseases, and p55 TNF receptor (TNFR) mediates the majority of TNF responses. The aim of the current study was to investigate the role of p55 TNFR expression in bone marrow-derived cells, in atherosclerotic lesion development. METHODS AND RESULTS Irradiated low-density lipoprotein receptor knock-out mice were reconstituted with either p55 TNFR knock-out or control haematopoietic stem cells to generate chimeras deficient or wild-type for p55 TNFR specifically in bone marrow-derived cells, including macrophages. Upon high fat feeding, p55 TNFR knock-out transplanted mice developed smaller atherosclerotic lesions. These lesions were characterized by the presence of smaller foam cells and a reduced macrophage foam cell area. They did not differ in other compositional characteristics as determined by quantification of inflammatory T-cell and neutrophil influx, apoptotic and necrotic cell death, and collagen content. In vitro studies confirmed a significant defect in modified lipoprotein endocytosis by p55 TNFR knock-out macrophages due to reduced scavenger receptor class A expression. Interestingly, plasma cytokine/chemokine profile analysis indicated that monocyte chemoattractant protein-1 (MCP-1) levels, a major chemokine involved in atherogenesis, were consistently and significantly lower in p55 TNFR knock-out transplanted mice compared with controls, before and after high fat feeding. CONCLUSION p55 TNFR expression in bone marrow-derived cells contributes to the development of atherosclerosis by enhancing lesional foam cell formation and by promoting the expression of pro-atherosclerotic chemokines such as MCP-1.
Collapse
Affiliation(s)
- Sofia Xanthoulea
- Department of Molecular Genetics, Cardiovascular Research Institute Maastricht, Maastricht University, Universiteitssingel 50, UNS 50/11, 6229ER Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Murabito JM, Keyes MJ, Guo CY, Keaney JF, Vasan RS, D'Agostino RB, Benjamin EJ. Cross-sectional relations of multiple inflammatory biomarkers to peripheral arterial disease: The Framingham Offspring Study. Atherosclerosis 2008; 203:509-14. [PMID: 18701106 DOI: 10.1016/j.atherosclerosis.2008.06.031] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2008] [Revised: 06/19/2008] [Accepted: 06/27/2008] [Indexed: 12/13/2022]
Abstract
BACKGROUND Emerging evidence suggests that different inflammatory biomarkers operate through distinct biologic mechanisms. We hypothesized that the relation to peripheral arterial disease (PAD) varies for individual markers. METHODS In a community-based sample we measured 12 biomarkers including plasma CD40 ligand, fibrinogen, lipoprotein-associated phospholipase-A2 mass and activity, osteoprotegerin, P-selectin, and tumor necrosis factor receptor 2 (TNFR2); and serum C-reactive protein, intracellular adhesion molecule-1, interleukin-6, monocyte chemoattractant protein-1, and myeloperoxidase in Framingham Offspring Study participants (n=2800, 53% women, mean age 61 years). We examined the cross-sectional relation of the biomarker panel to PAD using (1) a global test of significance to determine whether at least one of 12 biomarkers was related to PAD using the TEST statement in the LOGISTIC procedure in SAS and (2) stepwise multivariable logistic regression with forward selection of markers with separate models for (1) ankle-brachial index (ABI) category (<0.9, 0.9-1.0, >1.0) and (2) presence of clinical PAD (intermittent claudication or lower extremity revascularization). RESULTS The group of inflammatory biomarkers were significantly related to both ABI and clinical PAD (p=0.01 and p=0.02, respectively, multi-marker adjusted global significance test). Multivariable forward elimination regression retained interleukin-6 and TNFR2 as significantly associated with PAD. For one standard deviation change in interleukin-6 and TNFR2 concentrations, there was a 1.21 (p=0.005) and 1.19 (p=0.009) increased odds of a change in ABI level respectively. Similar results were observed for clinical PAD. CONCLUSION Interleukin-6 and TNFR2 were significantly associated with PAD independent of established risk factors and each other, suggesting that each marker represents a distinct biologic pathway.
Collapse
Affiliation(s)
- Joanne M Murabito
- National Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, MA 01702-5827, United States.
| | | | | | | | | | | | | |
Collapse
|
21
|
Holdt LM, Thiery J, Breslow JL, Teupser D. Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol 2008; 28:1097-103. [PMID: 18356551 DOI: 10.1161/atvbaha.108.165654] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND We have previously identified an atherosclerosis quantitative trait locus (QTL) on mouse chromosome (Chr) 12 in an F2-intercross of atherosclerosis-resistant FVB and atherosclerosis-susceptible C57BL/6 (B6) mice on the LDL-receptor deficient (LDL-/-) background. The aim of the present study was to identify potentially causative genes at this locus. METHODS AND RESULTS Expression QTL (eQTL) analysis of candidate genes in livers of F2-mice revealed that a disintegrin and metalloproteinase 17 (ADAM17) mRNA expression mapped to the physical position of ADAM17 on proximal Chr12 (21.6 Mb, LOD 3.3) and colocalized with the atherosclerosis QTL. The FVB allele was associated with significantly higher ADAM17 mRNA expression (39%) than the B6 allele. Likewise, ADAM17 mRNA levels in the parental strains were significantly elevated in FVB.LDLR-/- compared to B6.LDLR-/- mice in liver, macrophages, and aorta (68%, 58%, and 32%, respectively). Reporter gene assays revealed a genetic variant that might explain these expression differences. Moreover, FVB.LDLR-/- macrophages showed 5-fold increased PMA-induced shedding of tumor necrosis factor (TNF)-alpha and 32% increased release of TNF-receptor I compared to B6.LDLR-/-. The atherosclerosis locus and expression differences were confirmed in Chr12 interval-specific congenic mice. CONCLUSIONS Our data provide functional evidence for ADAM17 as a candidate gene of atherosclerosis susceptibility at the murine Chr12 QTL.
Collapse
Affiliation(s)
- Lesca M Holdt
- Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Liebigstr.27, 04103 Leipzig, Germany
| | | | | | | |
Collapse
|